Literature DB >> 17975806

Treatment of acquired factor X inhibitor by plasma exchange with concomitant intravenous immunoglobulin and corticosteroids.

Cyrus C Hsia1, Mike Keeney, Annmarie A Bosco, Anargyros Xenocostas.   

Abstract

A patient with spontaneous hemorrhage from multiple body sites was found to have markedly prolonged international normalized ratio (INR) and activated partial thromboplastin times (aPTT) with incomplete correction of aPTT on mixing studies using normal plasma. The cause of this severe hemorrhage was due to a specific factor X inhibitor. No underlying or associated diseases were found. Initial treatment with fresh frozen plasma, vitamin K, and recombinant activated factor VII (rFVIIa) was unsuccessful. However, therapy utilizing plasma exchange with concomitant intravenous immunoglobulin and corticosteroids resulted in a rapid and sustained normalization of factor X levels with a clinical hemostatic response. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17975806     DOI: 10.1002/ajh.21105

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  3 in total

1.  Successful treatment of a noninhibitory antibody-mediated acquired factor X deficiency in a patient with marginal-zone lymphoma.

Authors:  Annemarie Meenhuis; Rianne van Vliet; Francisca Hudig; Paula F Ypma; Martin R Schipperus; Martine J Hollestelle
Journal:  Clin Case Rep       Date:  2015-05-25

2.  Acquired Factor XI Inhibitor Presenting as Spontaneous Bilateral Subdural Hematoma in an Elderly Patient.

Authors:  Natale Vazzana; Luca Scarti; Chiara Beltrame; Antonella Picchi; Gianni Taccetti; Alberto Fortini
Journal:  Case Rep Hematol       Date:  2014-11-06

3.  Successful Treatment of Factor X Deficiency in a Patient with Lymphoplasmacytic Lymphoma with Bendamustine Plus Rituximab Regimen: A Case Report and Literature Review.

Authors:  Tarinee Rungjirajittranon; Yingyong Chinthammitr; Chattree Hantaweepant
Journal:  J Blood Med       Date:  2021-10-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.